Nilofer Azad

Associate Professor

19962018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 8 Similar Profiles
Neoplasms Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Pancreatic Neoplasms Medicine & Life Sciences
Rectal Neoplasms Medicine & Life Sciences
Epigenomics Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1996 2018

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer

Overman, M. J., Adam, L., Raghav, K., Wang, J., Kee, B., Fogelman, D., Eng, C., Vilar, E., Shroff, R., Dasari, A., Wolff, R., Morris, J., Karunasena, E., Pisanic, R., Azad, N. & Kopetz, S., Jan 1 2018, In : Annals of Oncology. 29, 1, p. 139-144 6 p., mdx688.

Research output: Contribution to journalArticle

CpG Islands
Colorectal Neoplasms
Adenocarcinoma
Phenotype
Adenomatous Polyposis Coli

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

Boyiadzis, M. M., Kirkwood, J. M., Marshall, J. L., Pritchard, C. C., Azad, N. & Gulley, J. L., May 14 2018, In : Journal for ImmunoTherapy of Cancer. 6, 1, 35.

Research output: Contribution to journalReview article

Drug Approval
United States Food and Drug Administration
Biomarkers
Programmed Cell Death 1 Receptor
Neoplasms

The role of epigenetic therapies in colorectal cancer

Baretti, M. & Azad, N., Jan 1 2018, (Accepted/In press) In : Current Problems in Cancer.

Research output: Contribution to journalArticle

Epigenomics
Colorectal Neoplasms
oxaliplatin
irinotecan
Therapeutics

Academic cancer center phase i program development

Frankel, A. E., Flaherty, K. T., Weiner, G. J., Chen, R., Azad, N., Pishvaian, M. J., Thompson, J. A., Taylor, M. H., Mahadevan, D., Lockhart, A. C., Vaishampayan, U. N., Berlin, J. D., Smith, D. C., Sarantopoulos, J., Riese, M., Saleh, M. N., Ahn, C. & Frenkel, E. P., Apr 1 2017, In : Oncologist. 22, 4, p. 369-374 6 p.

Research output: Contribution to journalComment/debate

Program Development
Neoplasms
Research
Research Personnel
Clinical Trials

ACR Appropriateness Criteria ® Resectable Pancreatic Cancer

Jones, W. E., Suh, W. W., Abdel-Wahab, M., Abrams, R. A., Azad, N., Das, P., Dragovic, J., Goodman, K. A., Jabbour, S. K., Konski, A. A., Koong, A. C., Kumar, R., Lee, P., Pawlik, T. M., Small, W. & Herman, J. M., 2017, In : American Journal of Clinical Oncology: Cancer Clinical Trials. 40, 2, p. 109-117 9 p.

Research output: Contribution to journalReview article

Pancreatic Neoplasms
Adenocarcinoma
Guidelines
Expert Testimony
Adjuvant Chemotherapy